That is hilarious. Which one of them are you talking about. The Alzheimers thought leader community. It could be any of them. That thought leader community led everyone down blind alley. That thought leader community was so desperate to win the race they all missed out very basic trials, rushed into ill advised phase 3 trials with no clear signals of efficacy in phase 2. One of the last ones standing is Bapi after data mining a phase 2. Pfizer/JNJ just extended their BAPI trial(if they had good results they could be getting a $10B drug approved now), but they delayed that to collect biomarkers. I will be very very surprised if they do not crash and burn like the rest of those Älzheimers thought leader community. The sad part is that all of those ill advised trials involved thousands and thousands of patients and their families. The FDA should be ashamed. They have burned up all their shareholders Alzheimers research funds chasing the wrong target. LLY entered their phase 3 semagacestat trial on biomarkers only, even though mouse tests had predicted it would worsen the condition and promote skin cancer. That is exactly what it did.
As I understand it it is harder to make stat sig in a small trial.
Give me Prana with a clear signal of efficacy in phase 2. Right now the only drug out there that I am interested in is Gammagard. Why, because it is the only other one to demonstrate efficacy at phase 2.
PBT efficacy was easy to spot because it reversed cognition loss.
They have since demonstrated two ways in mouse work why that happened.
"The data was negative" Link please. Or did you just make that up.
Market Data 
Markets 
AI
